Section 32, a venture capital fund, led a $76m Series B round in BigHat Biosciences, a biotechnology company, with participation from Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, and AME Cloud Ventures. “BigHat is ushering the next wave of personalized medicines with a sophisticated AI platform integrated with a next-generation lab that addresses the complexities and inefficiencies associated with biologics discovery. Section 32 is delighted to support BigHat’s mission and their quest to rapidly deliver safer and more effective antibody therapies for people suffering from today’s most challenging diseases,” Steve Kafka, PhD, Section 32 Managing Partner.